The bad news from AbbVie’s full year results was that inflammatory diseases blockbuster Humira “only” made around $19.2 billion as ex-US sales were hit by cheaper biosimilar competitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback